Paola sells MNKD 3.29: There was no major negative news to hurt the stock since the marketing rights of Afrezza were handed over to Sanofi SA (ADR) (NYSE:SNY). Of course, that became the biggest factor and dragger to leave the stock in the lurch.

However, if Sanofi is successful, the view looking forward may certainly represent a much brighter future for Afrezza and for investors who believed in the inhaled insulin, and the idea that Sanofi is committed to making the inhaled insulin a success. Today's price per share, lower than it was even before FDA approval, may reflect a view that Afrezza has failed to come very far. Naysayers point to the past six months and write that the Afrezza launch is a failure and that Sanofi is not really interested in promoting Afrezza. In the meantime, MannKind's price per share has been hammered down because neither of these two main points have been accomplished. And, if Sanofi is successful in their endeavors, it seems likely that Afrezza advertisements will then be seen on national television, and not just in a few scattered magazines.


Amber:
There are some current print ads for Afrezza in Time magazine and in some diabetes journals but these are likely just the very beginning of a Sanofi DTC campaign.

Willetta:
Sanofi's Direct To Consumer (DTC) advertising will come.

Ryan:
That should not be a problem as there is a great deal of leeway in setting the price of insulin and the Afrezza cartridge is very inexpensive to manufacture.

Gladys:
Additionally, as part of the negotiation process between Sanofi and health insurance providers, Sanofi will likely need to reduce the current cost of Afrezza in order to have Afrezza's cost to patients be in alignment with that of the injection pens.

Jessika:
It seems plausible that Sanofi can show Afrezza's need for the population of needle phobic diabetics.

Heike:
To this effect, Sanofi will have to offer something substantial to insurance companies in exchange for Tier 2 status.

Chanelle:
Sanofi must prove that there is a market demand, that Afrezza is safe and effective and Afrezza is able to perform the same benefit as injected insulin at the same cost.

Cathy:
After educating the nation's endocrinologists, getting Afrezza into Tier 2 status will be the most important accomplishment Sanofi must accomplish in the coming year.

Marvella:
Also, if there is already another drug in Tier 2 that performs the same benefit at a lower cost, it may be difficult for a new drug to gain Tier 2 status.

Willie:
Included in this evaluation is the idea that the drug must be proven to be safe and effective.

Mannkind Corp. (NASDAQ:MNKD)
//stockhand.net/us/?q=nasdaq%3Amnkd&id=583359